Talon Drops on FDA Review of Cancer Therapy: San Francisco MoverSamantha Zee
Talon Therapeutics Inc. fell the most since November 2010 after the U.S. Food and Drug Administration said it wants more time to review information about Talon’s Marqibo blood-cancer treatment.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Tesla Unveils ‘World’s Fastest Production Car’ and Electric Big Rig
- Norway Idea to Exit Oil Stocks Is ‘Shot Heard Around the World’
- Getting a Dog May Save Your Life, Especially If You’re Single
- The Questionable Math Behind Manafort’s Extravagant Home Renovations
- Musk Dusts Off the Fundraising Playbook With Semi, Roadster Orders